================================================================================
                    EPPP DOMAIN DESIGN - COMPLETE BREAKDOWN (v2.13)
================================================================================

Generated: 2026-01-02
Repository: https://github.com/mcdanielmjustin/EPPP-Domain-Design

================================================================================
                              MASTER SUMMARY TABLE
================================================================================

#  | Domain Name                                       | Thematic Lean                      | Personality            | Fund% | Mastery% | Type   | Anchor Pts | % Total
---|---------------------------------------------------|------------------------------------|-----------------------|-------|----------|--------|------------|--------
1  | Psychometrics & Research Methods                  | Statistical reasoning & validity   | "The methodologist"    | 60%   | 40%      | BIG 4  | 193        | 12.3%
2  | Lifespan & Developmental Stages                   | Stage theories & critical periods  | "The developmentalist" | 55%   | 45%      | BIG 4  | 174        | 11.1%
3  | Clinical Psychopathology                          | Genetics & etiology                | "The psychopathologist"| 30%   | 70%      | --     | 134        | 8.5%
4  | Psychotherapy Models, Interventions, & Prevention | Mechanisms of change               | "The interventionist"  | 25%   | 75%      | --     | 168        | 10.7%
5  | Social & Cultural Psychology                      | Identity & group dynamics          | "The contextualist"    | 50%   | 50%      | BIG 4  | 153        | 9.8%
6  | Workforce Development & Leadership                | Human performance & systems        | "The optimizer"        | 30%   | 70%      | --     | 172        | 11.0%
7  | Biopsychology                                     | Brain anatomy & neural circuits    | "The neuroscientist"   | 45%   | 55%      | BIG 4  | 192        | 12.3%
8  | Clinical Assessment & Interpretation              | Clinical interpretation & profiles | "The diagnostician"    | 30%   | 70%      | --     | 190        | 12.1%
9  | Psychopharmacology & Ethics                       | Drug mechanisms & ethical decisions| "The integrator"       | 30%   | 70%      | --     | 191        | 12.2%
---|---------------------------------------------------|------------------------------------|-----------------------|-------|----------|--------|------------|--------
   | TOTAL                                             |                                    |                       |       |          |        | 1,567      | 100%


================================================================================
                       SOURCE DOMAIN DISTRIBUTION (RAW COUNTS)
================================================================================

Source | Total | D1  | D2  | D3  | D4  | D5  | D6  | D7  | D8  | D9
-------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----
RMS    | 84    | 84  | --  | --  | --  | --  | --  | --  | --  | --
TES    | 84    | 64  | --  | --  | --  | --  | --  | --  | 20  | --
PAS    | 84    | 13  | --  | --  | --  | --  | --  | 4   | 67  | --
PHY    | 175   | 9   | 9   | 18  | --  | --  | --  | 96  | 9   | 35
LIF    | 175   | --  | 157 | --  | --  | 9   | --  | 9   | --  | --
PPA    | 208   | --  | 21  | 146 | 10  | --  | --  | 20  | 10  | --
CLI    | 193   | --  | --  | --  | 125 | 58  | --  | --  | --  | 10
ETH    | 196   | --  | --  | --  | --  | --  | --  | --  | 43  | 153
ORG    | 173   | --  | --  | --  | --  | --  | 173 | --  | --  | --
LEA    | 98    | 23  | --  | --  | 33  | --  | --  | 63  | --  | --
SOC    | 98    | --  | --  | --  | --  | 86  | --  | --  | --  | --
-------|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----
TOTAL  | 1,570 | 193 | 175 | 190 | 168 | 153 | 173 | 192 | 152 | 174


================================================================================
                    SOURCE DOMAIN DISTRIBUTION (PERCENTAGES)
================================================================================

Source | Total | D1    | D2    | D3    | D4    | D5    | D6    | D7    | D8    | D9
-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------
RMS    | 84    | 100%  | --    | --    | --    | --    | --    | --    | --    | --
TES    | 84    | 90%   | --    | --    | --    | --    | --    | --    | 10%   | --
PAS    | 84    | 15%   | --    | --    | --    | --    | --    | 5%    | 80%   | --
PHY    | 175   | 5%    | 5%    | 10%   | --    | --    | --    | 55%   | 5%    | 20%
LIF    | 175   | --    | 90%   | --    | --    | 5%    | --    | 5%    | --    | --
PPA    | 208   | --    | 10%   | 80%   | 5%    | --    | --    | --    | 5%    | --
CLI    | 193   | --    | --    | --    | 65%   | 30%   | --    | --    | --    | 5%
ETH    | 196   | --    | --    | --    | --    | --    | --    | --    | 22%   | 78%
ORG    | 173   | --    | --    | --    | --    | --    | 100%  | --    | --    | --
LEA    | 98    | 10%   | --    | --    | 20%   | --    | --    | 70%   | --    | --
SOC    | 98    | --    | --    | --    | --    | 100%  | --    | --    | --    | --


================================================================================
                           CONTENT MAPPING BY DOMAIN
================================================================================

Domain | Primary Sources                              | Content Areas
-------|----------------------------------------------|--------------------------------------------------
1      | RMS (100%), TES (90%), PAS (15%),           | Variables/data, research designs, inferential
       | PHY (5%), LEA (10%)                          | stats, reliability/validity, test interpretation,
       |                                              | conditioning theory
-------|----------------------------------------------|--------------------------------------------------
2      | LIF (90%), PHY (5%), PPA (10%)              | Piaget stages, attachment, moral development,
       |                                              | prenatal influences, physical milestones,
       |                                              | temperament
-------|----------------------------------------------|--------------------------------------------------
3      | PPA (80%), PHY (10%)                        | DSM disorders, genetic etiology, neurodevelop-
       |                                              | mental, schizophrenia, mood, anxiety, personality
       |                                              | disorders
-------|----------------------------------------------|--------------------------------------------------
4      | CLI (65%), PPA (5%), LEA (20%)              | CBT, psychodynamic, family/group therapy, brief
       |                                              | therapies, prevention, behavioral interventions
-------|----------------------------------------------|--------------------------------------------------
5      | SOC (100%), CLI (30%), LIF (5%)             | Attributions, biases, attitudes, persuasion,
       |                                              | group influence, prejudice, cultural identity
       |                                              | models
-------|----------------------------------------------|--------------------------------------------------
6      | ORG (100%)                                  | Leadership, motivation theories, job analysis,
       |                                              | selection, training, satisfaction, organizational
       |                                              | change
-------|----------------------------------------------|--------------------------------------------------
7      | PHY (55%), LEA (70%), LIF (5%), PAS (5%)    | Brain anatomy, neurotransmitters, sensation/
       |                                              | perception, memory/sleep, emotions/stress,
       |                                              | neurological disorders
-------|----------------------------------------------|--------------------------------------------------
8      | PAS (80%), TES (10%), PHY (5%),             | Wechsler/Stanford-Binet, MMPI-2, clinical tests,
       | PPA (5%), ETH (22%)                          | assessment ethics, forensic issues
-------|----------------------------------------------|--------------------------------------------------
9      | PHY (20%), CLI (5%), ETH (78%)              | Antipsychotics, antidepressants, anxiolytics,
       |                                              | APA ethics (Standards 1-8), confidentiality,
       |                                              | research ethics


================================================================================
                           BIG 4 MODEL CONFIGURATION
================================================================================

Position | Domain                         | Type   | Fund% | Mastery% | Rationale
---------|--------------------------------|--------|-------|----------|------------------------------------------
1        | Psychometrics & Research       | BIG 4  | 60%   | 40%      | Foundational - highest fundamental reinforcement
2        | Lifespan & Developmental       | BIG 4  | 55%   | 45%      | Second foundational - normal before pathology
5        | Social & Cultural              | BIG 4  | 50%   | 50%      | Mid-sequence reinforcement - contextualizes
7        | Biopsychology                  | BIG 4  | 45%   | 55%      | Pre-capstone - prerequisite for pharmacology


================================================================================
                              NON-BIG 4 DOMAINS
================================================================================

Position | Domain                                  | Fund% | Mastery% | Max Allowed | Status
---------|----------------------------------------|-------|----------|-------------|------------
3        | Clinical Psychopathology               | 30%   | 70%      | 30%         | At max
4        | Psychotherapy Models, Interventions... | 25%   | 75%      | 30%         | Under max
6        | Workforce Development & Leadership     | 30%   | 70%      | 30%         | At max
8        | Clinical Assessment & Interpretation   | 30%   | 70%      | 30%         | At max
9        | Psychopharmacology & Ethics            | 30%   | 70%      | 30%         | At max (Capstone)


================================================================================
                             PREREQUISITE CHAIN
================================================================================

Domain | Requires                    | Enables
-------|-----------------------------|-------------------------------------------------
1      | --                          | All domains (research literacy)
2      | Domain 1                    | Domain 3 (normal->abnormal), Domain 4, Domain 8
3      | Domain 2                    | Domain 4 (diagnosis->treatment)
4      | Domains 1, 2, 3             | Evidence-based practice
5      | --                          | Cultural competence across domains
6      | --                          | Applied psychology contexts
7      | --                          | Domain 9 (neurotransmitters->pharmacology)
8      | Domains 1, 7                | Clinical interpretation
9      | Domain 7 (CRITICAL)         | Capstone integration


================================================================================
                      ETH CONTENT DISTRIBUTION (v2.1)
================================================================================

ETH Subdomain                              | Count | Domain | Rationale
-------------------------------------------|-------|--------|---------------------------
Standards 1 & 2 (Overview, Competence)     | 27    | D9     | Foundational ethics
Standards 3 & 4 (Relationships, Confid.)   | 43    | D9     | Core ethical practice
Standards 5 & 6 (Advertising, Records)     | 32    | D9     | Professional practice
Standards 7 & 8 (Education, Research)      | 38    | D9     | Research ethics
Standards 9 & 10 (Assessment, Therapy)     | 33    | D8     | Assessment-specific ethics
Professional Issues (partial)              | ~10   | D8     | Forensic/assessment issues
Professional Issues (partial)              | ~13   | D9     | General professional ethics
-------------------------------------------|-------|--------|---------------------------
TOTAL                                      | 196   |        | 22% D8, 78% D9


================================================================================
                              SCAFFOLDING TIERS
================================================================================

Tier                  | Domains | Bloom's Level       | Webb's DOK          | Focus
----------------------|---------|---------------------|---------------------|------------------
Tier 1: Foundational  | 1, 2    | Remember, Understand| 1-2 (Recall, Skill) | Building blocks
Tier 2: Application   | 3, 4    | Apply, Analyze      | 2-3 (Skill, Strat.) | Clinical application
Tier 3: Context       | 5, 6, 7 | Analyze, Evaluate   | 3 (Strategic)       | Contextual factors
Tier 4: Integration   | 8, 9    | Evaluate, Create    | 3-4 (Strat., Ext.)  | Capstone integration


================================================================================
                       DOMAIN SIZE CONSTRAINTS (v2.12)
================================================================================

Domain | v2.0 Size  | v2.1 Size | v2.2 Size | v2.3 Size | v2.11 Size | v2.12 Size | Status
-------|------------|-----------|-----------|-----------|------------|------------|----------------------
1      | ~185-200   | 205       | 193       | 193       | 193        | 193        | OK (130-200)
2      | ~185-200   | 175       | 175       | 175       | 174        | 174        | OK (130-200)
3      | ~190-210   | 210       | 190       | 185       | 135        | 134        | OK (130-200)
4      | ~175-190   | 168       | 168       | 168       | 168        | 168        | OK (130-200)
5      | ~135-150   | 153       | 153       | 153       | 153        | 153        | OK (130-200)
6      | ~170-180   | 173       | 173       | 173       | 172        | 172        | OK (130-200)
7      | ~180-200   | 172       | 192       | 192       | 192        | 192        | OK (130-200)
8      | ~95-110    | 140       | 152       | 152       | 190        | 190        | OK (130-200)
9      | ~225-240   | 174       | 174       | 179       | 190        | 191        | OK (130-200)


================================================================================
                           VERSION HISTORY
================================================================================

Version | Date       | Changes
--------|------------|----------------------------------------------------------
v1.0    | Initial    | Original 9-domain structure with Assessment as 4th Big 4
v2.0    | Prior      | Biopsychology becomes 4th Big 4 (Position 7)
        |            | Assessment moved to non-Big 4 (Position 8)
        |            | Explicit prerequisite chain (Domain 7 -> Domain 9)
v2.1    | 2026-01-01 | Rebalanced to meet 130-200 anchor point constraint
        |            | Moved ETH Standards 9 & 10 to Domain 8
        |            | Moved partial ETH Professional Issues to Domain 8
        |            | ETH distribution: 22% D8, 78% D9
v2.2    | 2026-01-01 | Fixed actual size violations (D1: 205, D3: 210)
        |            | Moved TES: Test Score Interpretation to D8 (-12 from D1)
        |            | Moved PPA: Neurocognitive Disorders to D7 (-20 from D3)
        |            | All domains now verified within 130-200 range
v2.3    | 2026-01-01 | Reduced prerequisite violation (pharmacology in D3)
        |            | Moved 4 pharmacology anchor points from D3 to D9:
        |            | - Antipsychotics for tics, Serotonin for PE
        |            | - St. John's wort interactions (2 items)
        |            | D3: 190 → 185, D9: 174 → 179
v2.4    | 2026-01-01 | Raised Domain 9 fundamental % from 20% to 30%
        |            | Rationale: Drug classes, mechanisms, side effects,
        |            | and ethics standards require significant memorization
        |            | D9 now matches other non-Big 4 domains at 30%/70%
v2.5    | 2026-01-01 | Fixed Domain 3 personality/lean mismatch
        |            | Changed personality: "The nosologist" → "The psychopathologist"
        |            | Matches domain name; encompasses etiology + disease processes
v2.6    | 2026-01-01 | Documented cognitive-affective content distribution
        |            | Closed issue: content intentionally spread across D1,D2,D4,D7,D8
        |            | This is by design, not an omission
v2.7    | 2026-01-01 | Documented Domain 9 structure rationale
        |            | Closed issue: Pharma+Ethics share capstone integration theme
        |            | Both require integration of multiple prior domains
v2.8    | 2026-01-02 | Data quality fixes:
        |            | - Fixed 12 "Error: Rewrite failed" anchor points
        |            | - Merged 14 duplicate subdomain header pairs
        |            | - Disambiguated duplicate anchor point IDs with suffixes
v2.9    | 2026-01-02 | Content-based overrides and deduplication:
        |            | - Fixed Gender Dysphoria misplacement (stays in D3)
        |            | - Added drug term matching for pharmacology content
        |            | - Removed 3 duplicate anchor points
        |            | - Total: 1570 → 1567 anchor points
        |            | - Fixed Tier 3 Bloom's level: "Analyze, Apply" → "Analyze, Evaluate"
v2.10   | 2026-01-02 | Header normalization and quality review:
        |            | - Fixed Domain 5 "Bias" vs "Biases" duplicate headers
        |            | - Fixed Domain 9 split Ethics Standard headers
        |            | - Verified Little Albert entry is factually correct
        |            | - Documented tort law entry as source data quality issue
v2.11   | 2026-01-02 | Option D treatment migration from D3:
        |            | - Moved 38 psychosocial treatment items from D3 to D8
        |            | - Moved 6 biological treatment items from D3 to D9
        |            | - D3 now 135 (pure etiology/diagnosis focus)
        |            | - D8 now 190 (assessment + psychosocial treatments)
        |            | - D9 now 190 (pharmacology + biological treatments)
        |            | - Rationale: Treatment content belongs after D7 prerequisite
        |            | - Preserves Big 4 dispersed model at positions 1,2,5,7
v2.12   | 2026-01-02 | Data quality fixes and additional migration:
        |            | - Moved PPY [14] from D3 to D9 (stimulant/ADHD/SUD)
        |            | - D3 now 134, D9 now 191
        |            | - Normalized "LIFE" source code to "LIF"
        |            | - Fixed subdomain colon variations in D2
        |            | - Documented long entry [058] in D1 (923 chars)
        |            | - Verified no truncated entries in domain files
v2.13   | 2026-01-02 | Domain naming update for uniqueness:
        |            | - Renamed to avoid ASPPB and PrepJet collisions
        |            | - D1: "Psychometrics & Research Methods"
        |            | - D2: "Lifespan & Developmental Stages"
        |            | - D4: "Psychotherapy Models, Interventions, & Prevention"
        |            | - D6: "Workforce Development & Leadership"
        |            | - D8: "Clinical Assessment & Interpretation"
        |            | - D9: "Psychopharmacology & Ethics"
        |            | - All 9 domains now have unique names


================================================================================
                           KEY DESIGN PRINCIPLES
================================================================================

1. BIG 4 DISPERSED MODEL
   - Positions 1, 2, 5, 7 are Big 4 with higher fundamental %
   - Fundamental % decreases: 60% -> 55% -> 50% -> 45%
   - Non-Big 4 domains have max 30% fundamental

2. THEMATIC LEANS
   - Each domain has distinctive character driving content framing
   - Professional naming distinct from ASPPB

3. SCAFFOLDING
   - Bloom's Taxonomy progression (Remember -> Create)
   - Webb's DOK progression (Level 1-2 -> Level 3-4)
   - Prerequisite sequencing honored

4. CRITICAL PREREQUISITE
   - Biopsychology (D7) MUST precede Pharmacology (D9)
   - Neurotransmitters introduced in D7

5. SIZE CONSTRAINTS
   - Minimum: 130 anchor points per domain
   - Maximum: 200 anchor points per domain

================================================================================
                              END OF DOCUMENT
================================================================================
